

GVIRF Webinar

New Tuberculosis Vaccines for Adults & Adolescents: *Progress, Prospects, and Perspectives*

22 February 2024, 09.00 – 12.30 Eastern Time (UTC -5)

Final Agenda

Meeting Chair: Gavin Churchyard, Aurum Institute

Introduction by Sir Jeremy Farrar, World Health Organization (WHO)

Part 1: BCG is not enough

The burden of tuberculosis (TB), the urgent public health need, and the investment case for a new TB vaccine for adults and adolescents

Phumeza Tisile - TB Proof

Nebiat Gebreselassie - WHO

Richard White - London School of Hygiene & Tropical Medicine

Part 2: TB vaccines for adults and adolescents: a new class of vaccines on the horizon

Overview of the current vaccine pipeline, challenges and opportunities in vaccine product development

Mark Hatherill - South African Tuberculosis Vaccine Initiative

Ann Ginsberg - Bill & Melinda Gates Foundation

Panel 1 - Perspectives from vaccine developers and manufacturers (moderated by Raman Rao, Hilleman Labs)

Alex Schmidt - Gates Medical Research Institute

Ariane McCabe - GSK

Roxana Rustomjee - BioNTech

Eliana Pombo - Biofabri

Part 3: Innovation and new tools in TB vaccine development

Status of correlates development for TB vaccines, new antigenic targets and innovative models to measure them

Nicole Frahm - Gates Medical Research Institute

Munya Musvosvi - South African Tuberculosis Vaccine Initiative

Dave Lewinsohn - Oregon Health & Science University

Panel 2 - Do we have the tools we need to rationally identify and down-select new TB vaccine targets?

(moderated by Katrin Eichelberg, US National Institute of Allergy and Infectious Diseases)

Rasmus Mortensen - Statens Serum Institute

Rhea Coler - University of Washington

Helen McShane - University of Oxford

Tom Scriba - South African Tuberculosis Vaccine Initiative

Part 4: Preparing for success

Examining what is needed to prepare the pathway to policy, access and implementation of new TB vaccines for adults and adolescents, looking at demand, country readiness, and acceleration initiatives.

Shelly Malhotra - IAVI

Rupali Limaye - Smart4TB

Birgitte Giersing - WHO

Panel 3 - What are the priorities to prepare the pathway for new TB vaccine implementation, particularly for adults and adolescents? (moderated by Sonali Kochhar, University of Washington)

Rudzani Muloiwa - South African National Advisory Group on Immunization

Rakesh Aggarwal - Chair of WHO South-East Asia Regional Immunization Technical Advisory Group

Kudzai Makomva - Market Access Africa

Zacharia Kafuko - One Day Sooner

Closing by Kate O'Brien, WHO

Register at https://who.zoom.us/webinar/register/WN_B1qi05_KT9Om_EaGRhQGBg#/registration

Latest information available at: <https://www.technet-21.org/en/hot-topics-items/15105-gvirf>

Questions? Please email gvirf@who.int